You've got questions...we've got some answers
View in browser
Email 600x100

April 2025 Newsletter

Soliddd & HITLAB Live

HITLAB

This Thursday, April 24th, tune into HITLAB’s YouTube as Bill Taranto, founder, President and General Partner of the Merck Global Health Innovation Fund (MGHIF), LLC and VP Merck Global Health Innovation Group, interviews Soliddd's CEO Neal Weinstock. Neal promises to disclose some information about how our product development is coming along and our forthcoming next set of patient trials.

 

The event begins at 11:00am US Eastern time here: https://www.hitlab.org/symposia/april-2025/

Soliddd at HITLAB's Spring 2025 Innovators Summit

HITLAB

On May 6th we're back with HITLAB. Neal along with Soliddd's VP of operations Raffaello Galby will speak at HITLAB's Spring 2025 Innovators Summit, taking place during the second annual New York City Health Innovation Week. Under the title “Breaking Through the Noise: Health Tech, Fundraising Strategies, and Avoiding Time-Wasting Investors,” they will focus on Soliddd's investment journey.

 

More information on attending the HITLAB Spring 2025 Innovators Summit is available by clicking here.

SOLIDDDVISION_logo_rgb

You've got questions...we've got some answers

If you've reached out to us recently, you might have caught a glimpse of this information, but we're eager to share it with everyone...

 

TRIALS

Under the direction of principal investigator Dr. William Seiple, chief research officer at Lighthouse Guild in New York City, we conducted a significant number of pre-clinical trials with patients who have macular degeneration and Stargardt disease, using our prototype device in 2024. The trials resulted in broad success at increasing reading speed very strongly. More trials are coming this summer with a much more advanced testing device. 

 

PRODUCT AVAILABILITY

We are a young, little company making a hardware product. That’s hard to do. We are reliant on contractors and sometimes contractors take longer than expected to deliver their work, and sometimes mistakes are made and have to be corrected. Plus, sometimes we find a way to make our hardware and software better. We cannot predict exactly when the final product will be available, but we do want to make it available as soon as possible. Also, while we do not face significant regulatory issues in the United States, availability outside of the U.S. will depend on regulations we may face in each country.

 

PRICING

Sorry, we simply don’t know yet.

 

VISION HEALTH ISSUES OTHER THAN MACULAR DEGENERATION AND STARGARDT DISEASE

Our prototype greatly helped several patients with other conditions. We have conducted no rigorous testing for any of these other conditions and we cannot recommend use for anything other than macular degeneration or Stargardt disease. Of course, we want to investigate what we can do for other vision health issues. And certainly our SolidddVision glasses will be safe to use for all, so we will be collecting more information soon.

 

PRESCRIPTION COMPATIBILITY

You won’t need your prescription eyeglasses for nearsightedness or farsightedness, or prism glasses if you normally wear those while you’re wearing SolidddVision smartglasses. We don’t even need to use any special focusing lenses such as some other AR or VR glasses provide. Our optics project light in full focus directly onto the retina, regardless of whether the user is nearsighted or farsighted, and they aim images just right for wherever your eyes are looking.

 

We hope that answers some of your questions. It's an exciting time for Soliddd, as we hope it will be for you. 

 

All the best,

The Soliddd Team

Facebook
LinkedIn
X
Instagram

Soliddd and SolidddVision are trademarks of Soliddd Corp.

All other trade names are the property of their respective owners.

© 2025 Soliddd Corp. All rights reserved.

Our Privacy Policy

Soliddd Corp., 105 West 55th Street, Suite 8a, New York, NY 10019, United States

Unsubscribe Manage preferences